| Assay Method Information | |
| | Antiviral Activity Assay |
| Description: | A549-hACE2 cells were seeded 1.5 × 105 cells/well in DMEM complete into 24-well plates (0.5 mL/well) and then incubated for 16 h at 37 °C and 5% CO2. Cells were pretreated with compound for 1 h prior to infection performed using a clinical isolate of SARS-CoV-2 (SARS-CoV-2, isolate USA-WA1/ 2020) from BEI Resources. When 2-fold serial dilutions of compound (0.15−20 μM; remdesivir: 10 μM) added to the same volume of SARS-CoV-2 (final MOI = 0.01), the mixture was added to the monolayer cells and incubated for 1 h at 37 °C and 5% CO2. Afterward, the mixture was removed and replaced with 0.5 mL of infection media and incubated at 37 °C and 5% CO2. After 48 h, supernatants were harvested and processed for RT-qPCR. |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |